Top 50 Biosimilar Drug Manufacturers 2021

Top 50 Biosimilar Drug Manufacturers 2021

Top 50 Biosimilar Companies Report– Read on to determine how you can exploit the impending business opportunities emerging in this sector along with profile of top 50 companies operating in the market. The company profiles are divided into three segments including:

  • Major Players: Profiles of major 15 companies that account for over 60% market share in the global biosimilars market
  • Mid-Range Players: Profiles of 20 pioneering companies that account for significant market share and focuses on the innovative strategic collaborations and M&A
  • Ones to Watch – New Players: Profiles of 15 growing companies that are investing a huge amount of money in biosimilars R&D and focuses on new drug development
The global biosimilars market is projected to reach at a market value of USxx billion by 2023 with a lucrative CAGR during the forecast period. Visiongain’s report shows you the potential revenues streams to 2023, assessing the top 20 products, the major 50 key players, qualitative analysis, opportunities trends, and business prospects in the biosimilars industry.

How this report will benefit you

Visiongain’s new study is envisioned for anyone requiring commercial in-depth analyses for the global biosimilars market along with detailed company profiles of top 50 companies operating in the market. Our new study assists you to evaluate the overall global and regional market for biosimilars. Get the financial analysis of the overall market and major 50 player’s revenue predictions till 2023. High opportunity remains in this fast-growing Biosimilars Market. See how to exploit the existing opportunities in the market to gain maximum advantage in the near future.

Forecasts to 2023 and other analyses reveal the commercial prospects
  • In addition to profiles of top 50 biosimilar companies, our new study provides you with revenue forecasting to 2023
  • Includes growth rates for each segment and regional markets along with COVID-19 impact analysis
  • The profiles of the top 50 companies – descriptive and comprehensive data including company snapshot, overview, commercial developments, company shares & ranking, and detailed financial analysis with revenue and segment revenue forecast till 2023.
  • COVID-19 set to have a positive impact on the biosimilars industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.
Discover sales forecasts for the global and regional market forecasts from 2020-2023

Along with revenue prediction for the overall global market, there is segmentations by product for 20 major biosimilar drugs and 5 regional markets including North America, Europe, Asia Pacific, Latin America, and MEA.

Global market revenue and growth forecasts from 2020 to 2023 by product

The global biosimilars market revenue will surpass $16.57 billion in 2020 with a lucrative CAGR during the forecast period 2021-2023 to reach significant revenue growth to 2023. The major product considered in the report are:
  • Adalimumab
  • Etanercept
  • Trastuzumab
  • Infliximab
  • Insulin Glargine
  • Rituximab
  • Pegfilgrastim
  • Epoetin Alfa
  • Teriparatide
  • Bevacizumab
  • Insulin Lispro
  • Darbepoetin Alfa
  • Filgrastim
  • Enoxaparin
  • Eculizumab
  • Natalizumab
  • Cetuximab
  • Follitropin Alfa
  • Somatropin
  • Dornase Alfa
  • Other Biosimilars
Regional market revenue and growth forecasts from 2020 to 2023:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Leading companies and those seeking to enter the market

The report includes profiles of 50 major companies involved in the Biosimilar Market. The companies profiled in this report include:

Amgen Inc.; Novartis AG; Merck & Co., Inc.; Pfizer Inc.; Eli Lilly and Company; Biogen Inc.; Teva Pharmaceutical Industries Ld.; Celltrion Healthcare Co., Ltd.; Sanofi; Samsung Bioepis; Mylan N.V.; Fresenius Kabi AG; Intas Pharmaceuticals Ltd.; AbbVie Inc.; STADA Arzneimittel AG ; Coherus; Dr Reddy’s Laboratories Ltd.; Boehringer Ingelheim International GmbH; Daiichi Sankyo Co Ltd.; Biocon Ltd.; Nichi-Iko; Fujifilm Kyowa Kirin Biologics; Zydus Cadila; Apotex Inc.; Lupin Ltd.; PolPharma; Zhejiang Hisun Pharma; Cipla Ltd.; Generium; Torrent Pharma; Shenzhen Techdow Pharmaceutical; Mochida; Gedeon Richter Plc.; Aurobindo Pharma; USV Biologics; Egis Pharmaceuticals Plc.; Hetero; Ligand Pharmaceuticals; Xbrane Biopharma AB; Alvotech; Mabion S.A.; Reliance Life Sciences; Harvest Moon Pharmaceuticals; AryoGen; Jiangsu Simcere Pharmaceutical; Mundipharma International Ltd.; Kashiv Biosciences; Gene Techno Science; Avesthagen Pharma AG; Formycon AG.

Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

In summary, our 372-page report delivers you with the following knowledge:
  • Revenue forecasts from 2020 to 2023 for the global biosimilars market and subsegments (by products and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation
  • Detailed profiles of Top 50 Biosimilar Companies, with financial forecasts for net revenues, operating income, R&D investment, and biosimilar segment revenue
  • Revenue forecasts from 2020 to 2023 for 5 regional markets – See forecasts for the biosimilars market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Global Biosimilars market and Detailed Analysis of 50 Leading Companies. You will get the most recent data, opportunities, trends, and predictions.

The Top 50 Biosimilar Companies Report Forecast 2020-2023 will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional market or to understand strategic analysis of leading 50 companies of the biosimilars industry.Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1. Introduction to Biosimilars Market
1.2. Global Biosimilars Market Segmentation
1.3. Why You Should Read This Report
1.4. What This Report Delivers
1.5. Key Questions Answered By This Analytical Report Include:
1.6. Who is This Report For?
1.7. Methodology
1.1.1 COVID-19 Impact: Recovery Scenarios
1.1.2 Market Evaluation & Forecasting Methodology
1.8. Frequently Asked Questions (FAQs)
1.9. About Visiongain
2 Executive Summary
3 Global Biosimilars Market Size Forecast 2021-2023
3.1 Global Biosimilars Market: Revenue Forecast 2021-2023
3.2 Global Biosimilars Market: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
3.2.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
3.2.1.1 Growing demand for cost-effective biosimilar drugs and patent expiry of biologics during the forecast period
3.2.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
3.2.2.1 Players in the market will require to radically rethink their strategies
3.2.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
3.2.3.1 There will be fluctuating growth seen in the revenue and thus market will grow at an irregular rate due to the uneven upraise of COVID-19
3.2.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
3.2.4.1 The market will show moderately pessimistic growth
4 Global Biosimilars Market Size Forecast 2021-2023 by Product
4.1 Global Biosimilars Market by Product: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
4.1.1 "V" shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023
4.1.2 "U" shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023
4.1.3 "W" shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023
4.1.4 "L" shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023
4.2 Adalimumab
4.2.1 Adalimumab Market Forecast 2021-2023
4.2.1.1 Largest revenue-grossing segment in the global market
4.3 Etanercept
4.3.1 Etanercept Market Forecast 2021-2023
4.3.1.1 One of the best-selling biological products and a lucrative aim for developers of biosimilars
4.4 Trastuzumab
4.4.1 Trastuzumab Market Forecast 2021-2023
4.4.1.1 Widely used for the treatment of pateints with breast cancer
4.5 Infliximab
4.5.1 Infliximab Market Forecast 2021-2023
4.5.1.1 Infliximab segment is is projected to growt at a lucrative CAGR during the forecast period
4.6 Insulin Glargine
4.6.1 Insulin Glargine Market Forecast 2021-2023
4.6.1.1 In both Europe and the US, the patents on Lantus expired in 2014
4.7 Rituximab
4.7.1 Rituximab Market Forecast 2021-2023
4.7.1.1 It is one of the fastest growing segment in the global market
4.8 Pegfilgrastim
4.8.1 Pegfilgrastim Market Forecast 2021-2023
4.8.1.1 Patents for Neulasta expired in October 2015 in the US and expired in August 2017 in Europe
4.9 Epoetin Alfa
4.9.1 Epoetin Alfa Market Forecast 2021-2023
4.9.1.1 Hospira (Pfizer) acquired approval in the US in May 2018 for its epoetin alfa biosimilar, Retacrit (epoetin alfa-epbx)
4.10 Teriparatide
4.10.1 Teriparatide Market Forecast 2021-2023
4.10.1.1 This segment is growing at a lucrative CAGR during the forecast period
4.11 Bevacizumab
4.11.1 Bevacizumab Market Forecast 2021-2023
4.11.1.1 Mainly used to treat different cancers including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers
4.12 Insulin Lispro
4.12.1 Insulin Lispro Market Forecast 2021-2023
4.12.1.1 Insulin lispro is a fast acting analogue of insulin used for the treatment of individuals with type 1 or type 2 diabetes
4.13 Darbepoetin Alfa
4.13.1 Darbepoetin Alfa Market Forecast 2021-2023
4.13.1.1 Aranesp's patents expired in July 2016 in Europe and will expire in the U.S. by May 2024
4.14 Filgrastim
4.14.1 Filgrastim Market Forecast 2021-2023
4.14.1.1 Filgrastim is a colony-stimulating factor (G-CSF) in granulocytes
4.15 Enoxaparin
4.15.1 Enoxaparin Market Forecast 2021-2023
4.15.1.1 Enoxaparin is used for the prevention and treatment of pulmonary embolism or deep vein thrombosis
4.16 Eculizumab
4.16.1 Eculizumab Market Forecast 2021-2023
4.16.1.1 The patents on Soliris will expire in March 2021 in the US and in May 2020 in Europe
4.17 Natalizumab
4.17.1 Natalizumab Market Forecast 2021-2023
4.17.1.1 In September 2019, Sandoz announced that it will commercialize the Polpharma's natalizumab biosimilar while Polpharma will be responsible for development and manufacturing
4.18 Cetuximab
4.18.1 Cetuximab Market Forecast 2021-2023
4.18.1.1 The major vendors including Amgen, BioXPress, Celltrion, and MabTech-Sorrento have cetuximab biosimilar under development
4.19 Follitropin Alfa
4.19.1 Follitropin Alfa Market Forecast 2021-2023
4.19.1.1 There are several popular biosimilars of Follitropin alfa available in the market
4.20 Somatropin
4.20.1 Somatropin Market Forecast 2021-2023
4.20.1.1 It is a peptide hormone in humans and other animals that stimulates growth, cell reproduction, and cell regeneration
4.21 Dornase Alfa
4.21.1 Dornase Alfa Market Forecast 2021-2023
4.21.1.1 In September 2019, the Russian biotech firm Generium and the Swiss cell-line manufacturer Selexis obtained approval for their biological dornase alfa biosimilar Tigerase
4.22 Other Biosimilars
4.22.1 Other Biosimilars Market Forecast 2021-2023
4.22.1.1 Growing demand for advanced and affordable drugs expected to drive the segment growth
5 Regional Biosimilars Market Forecasts 2021-2023
5.1 What Were the Leading Regional Markets for Biosimilar in 2020?
5.2 Global Biosimilars Market by Region: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
5.2.1 "V" shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023
5.2.2 "U" shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023
5.2.3 "W" shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023
5.2.4 "L" shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023
5.3 North America
5.3.1 North America Biosimilars Market Forecast 2021-2023
5.3.1.1 Increasing Number of Drug Approvals
5.3.1.2 Presence of Advanced Healthcare Infrastructure and Government Funding
5.3.2 North America Biosimilars Market: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
5.4 Europe
5.4.1 Europe Biosimilars Market Forecast 2021-2023
5.4.1.1 The Largest Revenue Grossing Region
5.4.1.2 A Hub for Advanced Drugs Development and Production
5.4.2 Europe Biosimilars Market: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
5.5 Asia Pacific
5.5.1 Asia Pacific Biosimilars Market Forecast 2021-2023
5.5.1.1 Increasing Prevalence of Cancer & Autoimmune Diseases
5.5.1.2 An Attractive Market for the Industry Looking to Expand Within the Region
5.5.2 Asia Pacific Biosimilars Market: COVID-19 Recovery Forecasts (V, U, W, L) 2021-2023
5.6 Latin America
5.6.1 Latin America Biosimilars Market Forecast 2021-2023
5.6.1.1 Government Support for Development of the Healthcare Sector
5.6.1.2 Availability of Skilled and Inexpensive Workforce
5.6.2 Latin America Biosimilars Market: COVID-19 Recovery Forecasts (V, U, W, L) 2021-2023
5.7 MEA
5.7.1 MEA Biosimilars Market Forecast 2021-2023
5.7.1.1 Developing Healthcare Infrastructure
5.7.1.2 Presence of huge growth opportunities
5.7.2 MEA Biosimilars Market: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
6 Biosimilars Market Forecasts 2021-2023: Major Players
6.1 COVID-19 Impact: Biosimilars Industry
6.2 Company Share Analysis: Biosimilars Market 2020
6.3 Amgen Inc.
6.3.1 Amgen Inc.: Company Snapshot
6.3.2 Amgen: Company Overview
6.3.3 Amgen: Biosimilars Overview
6.3.4 Amgen: Geographical Locations
6.3.5 Amgen: Strategic Planning
6.3.6 Amgen: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.3.7 Amgen Inc.: Product Portfolio
6.3.8 Amgen Inc.: Biosimilar Product Pipeline
6.3.9 Amgen Inc.: Company Facilities
6.3.10 Amgen: Latest Developments
6.4 Novartis AG
6.4.1 Novartis AG: Company Snapshot
6.4.2 Novartis AG: Company Overview
6.4.3 Novartis AG: Biosimilars Overview
6.4.4 Novartis AG: Financials, 2018-2023
6.4.4.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.4.5 Novartis AG: Product Portfolio
6.4.6 Novartis AG: Latest Developments
6.5 Merck & Co., Inc.
6.5.1 Merck & Co., Inc.: Company Snapshot
6.5.2 Merck & Co., Inc.: Company Overview
6.5.3 Merck & Co., Inc.: Biosimilars Overview
6.5.4 Merck & Co., Inc.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.5.5 Merck & Co., Inc.: Product Portfolio
6.5.6 Merck & Co., Inc.: Latest Developments
6.6 Pfizer Inc.
6.6.1 Pfizer Inc.: Company Snapshot
6.6.2 Pfizer Inc.: Company Overview
6.6.3 Pfizer Inc.: Biosimilars Overview
6.6.4 Pfizer Inc.: Manufacturing Overview
6.6.5 Pfizer Inc.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.6.6 Pfizer Inc.: Product Portfolio
6.6.7 Pfizer Inc.: Latest Developments
6.7 Eli Lilly and Company
6.7.1 Eli Lilly and Company: Company Snapshot
6.7.2 Eli Lilly and Company: Company Overview
6.7.3 Eli Lilly and Company: Biosimilars Overview
6.7.4 Eli Lilly and Company: Regional Presence
6.7.5 Eli Lilly and Company: Company Facilities
6.7.6 Eli Lilly and Company: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.7.7 Eli Lilly and Company: Product Portfolio
6.7.8 Eli Lilly and Company: Latest Developments
6.8 Biogen Inc.
6.8.1 Biogen Inc.: Company Snapshot
6.8.2 Biogen Inc.: Company Overview
6.8.3 Biogen Inc.: Biosimilars Overview
6.8.4 Biogen Inc.: Manufacturing Operations
6.8.5 Biogen Inc.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.8.6 Biogen Inc.: Product Portfolio
6.8.7 Biogen Inc.: Latest Developments
6.9 Teva Pharmaceutical Industries Ltd.
6.9.1 Teva Pharmaceutical Industries Ltd.: Company Snapshot
6.9.2 Teva Pharmaceutical Industries Ltd.: Company Overview
6.9.3 Teva Pharmaceutical Industries Ltd.: Biosimilars Overview
6.9.4 Teva Pharmaceutical Industries Ltd.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.9.5 Teva Pharmaceutical Industries: Pharmaceutical Production
6.9.6 Teva Pharmaceutical Industries Ltd.: Product Portfolio
6.9.7 Teva Pharmaceutical Industries Ltd.: Latest Developments
6.10 Celltrion Healthcare Co.,Ltd.
6.10.1 Celltrion Healthcare Co.,Ltd.: Company Snapshot
6.10.2 Celltrion Healthcare Co.,Ltd.: Company Overview
6.10.3 Celltrion Healthcare Co., Ltd.: Manufacturing Facilities
6.10.4 Celltrion Healthcare Co.,Ltd.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.10.5 Celltrion Healthcare Co.,Ltd.: Product Portfolio
6.10.6 Celltrion Healthcare Co., Ltd.: Product in Details
6.10.7 Celltrion Healthcare Co.,Ltd.: Latest Developments
6.11 Sanofi
6.11.1 Sanofi: Company Snapshot
6.11.2 Sanofi: Company Overview
6.11.3 Sanofi: Biosimilar Overview
6.11.4 Sanofi: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.11.5 Sanofi: Product Portfolio
6.11.6 Sanofi: Latest Developments
6.12 Samsung Bioepis
6.12.1 Samsung Bioepis: Company Snapshot
6.12.2 Samsung Bioepis: Company Overview
6.12.3 Samsung Bioepis: Biosimilars Overview
6.12.4 Samsung Bioepis: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.12.5 Samsung Bioepis: Product Portfolio
6.12.6 Samsung Bioepis: Latest Developments
6.13 Mylan N.V.
6.13.1 Mylan N.V.: Company Snapshot
6.13.2 Mylan N.V.: Company Overview
6.13.3 Mylan N.V.: Biosimilars Overview
6.13.4 Mylan N.V.: Collaboration and Licensing Agreements
6.13.5 Mylan N.V.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.13.6 Mylan N.V.: Product Portfolio
6.13.7 Mylan N.V.: Latest Developments
6.14 Fresenius Kabi AG
6.14.1 Fresenius Kabi AG: Company Snapshot
6.14.2 Fresenius Kabi AG: Company Overview
6.14.3 Fresenius Kabi AG: Biosimilars Overview
6.14.4 Fresenius Kabi AG: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.14.5 Fresenius Kabi AG: Product Portfolio
6.14.6 Fresenius Kabi AG: Headquarters
6.14.7 Fresenius Kabi AG: Manufacturing Facilities
6.14.8 Fresenius Kabi AG: Latest Developments
6.15 Intas Pharmaceuticals Ltd.
6.15.1 Intas Pharmaceuticals Ltd.: Company Snapshot
6.15.2 Intas Pharmaceuticals Ltd.: Company Overview
6.15.3 Intas Pharmaceuticals Ltd.: Biosimilar Overview
6.15.4 Intas Pharmaceuticals Ltd.: R&D and Manufacturing Facilities
6.15.5 Intas Pharmaceuticals Ltd.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.15.6 Intas Pharmaceuticals Ltd.: Product Portfolio
6.15.7 Intas Pharmaceuticals Ltd.: Latest Developments
6.16 AbbVie Inc.
6.16.1 AbbVie Inc.: Company Snapshot
6.16.2 AbbVie Inc.: Company Overview
6.16.3 AbbVie Inc. & Allergan plc acquisition & Biosimilar
6.16.4 AbbVie Inc.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.16.5 AbbVie Inc.: Product Portfolio
6.16.6 AbbVie Inc.: Latest Developments
6.17 STADA Arzneimittel AG
6.17.1 STADA Arzneimittel AG: Company Snapshot
6.17.2 STADA Arzneimittel AG: Company Overview
6.17.3 STADA Arzneimittel AG: Biosimilars Overview
6.17.4 STADA Arzneimittel AG: Recent Biosimilars-Related Partnerships
6.17.5 STADA Arzneimittel AG: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
6.17.6 STADA Arzneimittel AG: Product Portfolio
6.17.7 STADA Arzneimittel AG: Latest Developments
7 Biosimilars Market Forecasts 2021-2023: Mid-Range Players
7.1 Coherus
7.1.1 Coherus: Company Snapshot
7.1.2 Coherus: Company Overview
7.1.3 Coherus: Biosimilars Overview
7.1.4 Coherus: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.1.5 Coherus: Product Portfolio
7.1.6 Coherus: Latest Developments
7.2 Dr. Reddy’s Laboratories Ltd.
7.2.1 Dr. Reddy’s Laboratories Ltd.: Company Snapshot
7.2.2 Dr. Reddy’s Laboratories Ltd.: Company Overview
7.2.3 Dr. Reddy’s Laboratories Ltd.: Biosimilar Overview
7.2.4 Dr. Reddy’s Laboratories Ltd.: Future Strategies
7.2.5 Dr. Reddy’s Laboratories Ltd.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.2.6 Dr. Reddy’s Laboratories Ltd.: Product Portfolio
7.2.7 Dr. Reddy’s Laboratories Ltd.: Latest Developments
7.3 Boehringer Ingelheim International GmbH
7.3.1 Boehringer Ingelheim International GmbH: Company Snapshot
7.3.2 Boehringer Ingelheim International GmbH: Company Overview
7.3.3 Boehringer Ingelheim International GmbH: Biosimilars Overview
7.3.4 Boehringer Ingelheim International GmbH: Manufacturing Capacity
7.3.5 Boehringer Ingelheim International GmbH: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.3.6 Boehringer Ingelheim International GmbH: Product Portfolio
7.3.7 Boehringer Ingelheim International GmbH: Latest Developments
7.4 Daiichi Sankyo Co Ltd.
7.4.1 Daiichi Sankyo Co Ltd.: Company Snapshot
7.4.2 Daiichi Sankyo Co Ltd.: Company Overview
7.4.3 Daiichi Sankyo Co Ltd.: Biosimilar Overview
7.4.4 Daiichi Sankyo Co Ltd.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.4.5 Daiichi Sankyo Co Ltd.: Product Portfolio
7.4.6 Daiichi Sankyo Co Ltd.: Company Facilities
7.4.7 Daiichi Sankyo Co Ltd.: Latest Developments
7.5 Biocon Ltd.
7.5.1 Biocon Ltd.: Company Snapshot
7.5.2 Biocon Ltd.: Company Overview
7.5.3 Biocon Biologics India Limited
7.5.4 Biocon Ltd.: Biosimilars Overview
7.5.5 Biocon Ltd.: Biosimilars Business Strategic Focus
7.5.6 Biocon Ltd.: Manufacturing Facilities
7.5.7 Biocon Ltd.: Biosimilars Manufacturing Capacity Expansion
7.5.8 Biocon Ltd.: Expanding Commercial Footprint
7.5.9 Biocon Ltd.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.5.10 Biocon Ltd.: Product Portfolio
7.5.11 Biocon Ltd.: Biocon Biologics & Mylan Partnered Portfolio, 2020
7.5.12 Biocon Ltd.: Latest Developments
7.6 Nichi-iko
7.6.1 Nichi-iko: Company Snapshot
7.6.2 Nichi-iko: Company Overview
7.6.3 Nichi-Iko Pharmaceutical Co. Ltd.: Biosimilars Overview
7.6.4 Nichi-iko: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
7.6.5 Nichi-iko: Product Portfolio
7.6.6 Nichi-iko: Latest Developments
7.7 Fujifilm Kyowa Kirin Biologics
7.7.1 Fujifilm Kyowa Kirin Biologics: Company Snapshot
7.7.2 Fujifilm Kyowa Kirin Biologics: Company Profile
7.7.3 Fujifilm Kyowa Kirin Biologics: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.7.4 Fujifilm Kyowa Kirin Biologics: Product Portfolio
7.7.5 Fujifilm Kyowa Kirin Biologics: Latest Developments
7.8 Zydus Cadila
7.8.1 Zydus Cadila: Company Snapshot
7.8.2 Zydus Cadila: Company Overview
7.8.3 Zydus Cadila: Biosimilars Overview
7.8.4 Zydus Cadila: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.8.5 Zydus Cadila: Product Portfolio
7.8.6 Zydus Cadila: Latest Developments
7.9 Apotex
7.9.1 Apotex: Company Snapshot
7.9.2 Apotex Inc.: Company Overview
7.9.3 Apotex Inc.: Biosimilar Overview
7.9.4 Apotex: Manufacturing Facility and Regional Presence
7.9.5 Apotex: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
7.9.6 Apotex: Product Portfolio
7.9.7 Apotex: Latest Developments
7.10 Lupin
7.10.1 Lupin: Company Snapshot
7.10.2 Lupin: Company Overview
7.10.3 Lupin Limited: Biosimilars Overview
7.10.4 Lupin: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.10.5 Lupin: Product Portfolio
7.10.6 Lupin: Latest Developments
7.11 PolPharma
7.11.1 PolPharma: Company Snapshot
7.11.2 PolPharma: Company Overview
7.11.3 Polpharma: Biosimilars Overview
7.11.4 PolPharma: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
7.11.5 PolPharma: Biosimilars Pipeline
7.11.6 PolPharma: Latest Developments
7.12 Zhejiang Hisun Pharma
7.12.1 Zhejiang Hisun Pharma: Company Snapshot
7.12.2 Zhejiang Hisun Pharma: Company Overview
7.12.3 Zhejiang Hisun Pharma: Biosimilars Overview
7.12.4 Zhejiang Hisun Pharma: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
7.12.5 Zhejiang Hisun Pharma: Biologics Manufacturing Service
7.12.6 Zhejiang Hisun Pharma: Latest Developments
7.13 Cipla Ltd.
7.13.1 Cipla Ltd.: Company Snapshot
7.13.2 Cipla Ltd.: Company Overview
7.13.3 Cipla Ltd.: Manufacturing Investment
7.13.4 Cipla Ltd.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Profit Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.13.5 Cipla Ltd.: Product Portfolio
7.13.6 Cipla Ltd.: Latest Developments
7.14 Generium
7.14.1 Generium: Company Snapshot
7.14.2 Generium: Company Overview
7.14.3 Generium: Biosimilars Overview
7.14.4 Generium: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
7.14.5 Generium: Product Portfolio
7.14.6 Generium: Latest Developments
7.15 Torrent Pharma
7.15.1 Torrent Pharma: Company Snapshot
7.15.2 Torrent Pharma: Company Overview
7.15.3 Torrent Pharma: Biosimilars Overview
7.15.4 Torrent Pharma: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.15.5 Torrent Pharma: Product Portfolio
7.15.6 Torrent Pharma: Latest Developments
7.16 Shenzhen Techdow Pharmaceutical
7.16.1 Shenzhen Techdow Pharmaceutical: Company Snapshot
7.16.2 Shenzhen Techdow Pharmaceutical: Company Overview
7.16.3 Shenzhen Techdow Pharmaceutical: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
7.16.4 Shenzhen Techdow Pharmaceutical: Product Portfolio
7.16.5 Shenzhen Techdow Pharmaceutical: Latest Developments
7.17 Mochida
7.17.1 Mochida: Company Snapshot
7.17.2 Mochida: Company Overview
7.17.3 Mochida Pharmaceutical Co. Ltd.: Biosimilars Overview
7.17.4 Mochida: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Net Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.17.5 Mochida: Product Portfolio
7.17.6 Mochida: Latest Developments
7.18 Gedeon Richter Plc.
7.18.1 Gedeon Richter Plc.: Company Snapshot
7.18.2 Gedeon Richter Plc.: Company Overview
7.18.3 Gedeon Richter Plc.: Biosimilar Overview
7.18.4 Gedeon Richter Plc.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.18.5 Gedeon Richter Plc.: Product Portfolio
7.18.6 Gedeon Richter Plc.: Latest Developments
7.19 Aurobindo Pharma
7.19.1 Aurobindo Pharma: Company Snapshot
7.19.2 Aurobindo Pharma: Company Overview
7.19.3 Aurobindo Pharma: Biosimilars Overview
7.19.4 Aurobindo Pharma: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
7.19.5 Aurobindo Pharma: Product Portfolio
7.19.6 Aurobindo Pharma: Latest Developments
7.20 USV BIOLOGICS
7.20.1 USV BIOLOGICS: Company Snapshot
7.20.2 USV BIOLOGICS: Company Overview
7.20.3 USV BIOLOGICS: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
7.20.4 USV BIOLOGICS: Product Pipeline
7.20.5 USV BIOLOGICS: Latest Developments
8 Biosimilars Market Forecasts 2021-2023: New Players
8.1 Egis Pharmaceuticals Plc.
8.1.1 Egis Pharmaceuticals Plc.: Company Snapshot
8.1.2 Egis Pharmaceuticals Plc.: Company Overview
8.1.3 EGIS PLC: Biosimilars Overview
8.1.4 Egis Pharmaceuticals Plc.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
8.1.5 Egis Pharmaceuticals Plc.: Product Portfolio
8.1.6 Egis Pharmaceuticals Plc.: Latest Developments
8.2 Hetero
8.2.1 Hetero: Company Snapshot
8.2.2 Hetero: Company Overview
8.2.3 Hetero: Biosimilars Overview
8.2.4 Hetero: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
8.2.5 Hetero: Product Portfolio
8.2.6 Hetero: Latest Developments
8.3 Ligand Pharmaceuticals
8.3.1 Ligand Pharmaceuticals: Company Snapshot
8.3.2 Ligand Pharmaceuticals: Company Overview
8.3.3 Ligand Pharmaceuticals Inc: Biosimilars Overview
8.3.4 Ligand Pharmaceuticals: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
8.3.5 Ligand Pharmaceuticals: Product Portfolio
8.3.6 Ligand Pharmaceuticals: Latest Developments
8.4 Xbrane
8.4.1 Xbrane: Company Snapshot
8.4.2 Xbrane: Company Overview
8.4.3 Xbrane Biopharma AB: Biosimilars Overview
8.4.4 Xbrane: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
8.4.5 Xbrane: Product Portfolio
8.4.6 Xbrane: Latest Developments
8.5 Alvotech
8.5.1 Alvotech: Company Snapshot
8.5.2 Alvotech: Company Overview
8.5.3 Alvotech: R&D and Manufacturing of Biosimilars
8.5.4 Alvotech: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
8.5.5 Alvotech: Product Portfolio
8.5.6 Alvotech: Latest Developments
8.6 Mabion S.A.
8.6.1 Mabion S.A.: Company Snapshot
8.6.2 Mabion S.A.: Company Overview
8.6.3 Mabion S.A.: Biosimilar Overview
8.6.4 Mabion S.A.: Ground-breaking Research & Development Capacity
8.6.5 Mabion S.A.: MabionCD20
8.6.6 Mabion S.A.: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
8.6.7 Mabion S.A.: Product Portfolio
8.6.8 Mabion S.A.: Latest Developments
8.7 Reliance Life Sciences
8.7.1 Reliance Life Sciences: Company Snapshot
8.7.2 Reliance Life Sciences: Company Overview
8.7.3 Reliance Life Sciences: Biosimilars Overview
8.7.4 Reliance Life Sciences: Financials, 2018-2023
6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook